Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

ng.  

"These very encouraging results to date support further evaluation of CCX140 in advanced clinical trials for the treatment of patients with type 2 diabetes," said Thomas J. Schall, President and Chief Executive Officer of ChemoCentryx.  "In addition to a high degree of target specificity and metabolic benefits, CCX140 is clearly differentiated from other marketed products with its added potential to treat the underlying mechanisms of type 2 diabetes and associated complications such as nephropathy and retinopathy.   The results of these trials continue to lead us to believe that CCX140 will be a meaningful and novel treatment option for patients who suffer from type 2 diabetes."

About Type 2 Diabetes and CCR2

Type 2 diabetes is a common metabolic disorder of high blood glucose associated with insulin resistance. It is differentiated from type 1 diabetes in which the primary defect is the inability of the pancreas to produce insulin. Patients with type 2 diabetes often require medication to maintain glucose homeostasis. The incidence of type 2 diabetes has reached epidemic proportions, associated in part with the rise in the incidence of weight gain and sedentary lifestyle. Despite available therapies, such as metformin, sulfonylureas, thiazolidinediones, incretin mimetics and other therapies, an unmet medical need for safe and convenient treatments persists.

For decades, the presence of systemic markers of inflammation has been known to increase with obesity. The adipose tissue has been shown to express multiple inflammatory cytokines, including TNF-a, IL-6, and MCP-1, the expression levels of which correlate with the degree of adiposity. Several of these mediators, including MCP-1 (also called chemokine ligand 2 (CCL2)), the main ligand for CCR2, have been shown to impair insulin-stimulated glucose uptake in adipose tissue, skeletal muscle and liver, providing a link between inflamed adipose tissue and insu
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional ... Toronto -based 3D visualization leader ... Congress of Neurological Surgeons Annual Meeting that they ... for brain surgery. The collaboration is the first ... combination to improve patient outcomes. NICO,s BrainPath® interventional ...
(Date:10/20/2014)... 20, 2014   BioNano Genomics announced today achievement ... to collect human data at 30X depth, sufficient for a ... new capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s ... be showcasing this advancement at the American Society for ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Site Solutions Summit, an annual conference of premier clinical ... their 2010 Site Solutions Summit Eagle Awards to Eli ... PPD, Inc., as the top contract research organization (CRO). ... CRO for their commitment to outstanding leadership, professionalism, integrity, ...
... Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will ... 2010 on Wednesday, November 3, 2010.  The company added ... R. Abbott, its Senior Vice President and Chief Financial ... at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) ...
Cached Medicine Technology:Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting 2Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting 3Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting 4Cardiogenesis Corporation to Report 2010 Third Quarter Results on November 3rd 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... By Dennis Thompson ... -- U.S. health officials on Monday officially tightened guidelines for ... with no skin exposure and use of a respirator at ... Prevention decided to issue the tougher rules after two Dallas ... diagnosed in the United States, Liberian national Thomas Eric Duncan. ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... tests, but side effects concern researchers , FRIDAY, Jan. ... longer prescribed may find new life as an effective ... as clorgyline, hasn,t been tested in humans as a ... can reduce and even reverse the symptoms of heart ...
... in those who worked out while dieting , THURSDAY, Jan. ... this year, consider adding a regular exercise program while you,re ... outcomes -- such as lower blood pressure and cholesterol levels ... , "It,s better to lose weight with a combination of ...
... sleep nightly, study finds, , FRIDAY, Jan. 8 (HealthDay News) ... teachers of adolescents, a new study finds that most U.S. ... the study found that almost 69 percent of high school ... about 8 percent of teens get the optimal amount -- ...
... messaging from quitline specialists (i.e., stressing the benefits ... those who received standard-care messaging (i.e., potential losses ... a new study published online January 7 in ... . Researchers also established that quitline specialists can ...
... to genetically modify human embryonic stem cells. Their approach, which ... genes, will make possible the rapid development of stem cell ... diseases and as testbeds on which to screen potential treatments, ... whole human embryonic stem cell field. Otherwise, there,s really few ...
... has shown that metformin, a drug often used in the ... patients who have both diabetes and advanced heart failure. The ... by researchers at the David Geffen School of Medicine ... "There may be over two million individuals with heart failure ...
Cached Medicine News:Health News:Older Antidepressant May Treat Heart Failure 2Health News:For Fitness, Cutting Calories May Not Be Enough 2Health News:For Fitness, Cutting Calories May Not Be Enough 3Health News:Two-Thirds of American Teens Need More Shut-Eye 2Health News:Two-Thirds of American Teens Need More Shut-Eye 3Health News:Quitline messages that stress benefits of quitting may improve smoking cessation 2Health News:Biologists develop efficient genetic modification of human embryonic stem cells 2Health News:Biologists develop efficient genetic modification of human embryonic stem cells 3Health News:UCLA study shows metformin is safe for patients with advanced heart failure and diabetes mellitus 2
... helps protect you against needlestick injury. Its ... exposure to a contaminated needle, provides easy ... for use in high-risk environments. The one-handed ... for activation of the safety mechanism while ...
... The Omni-Flex System provides the ... in the middle of surgery ... on the incision. The system ... be stable for large patients ...
... The genuine BOOKWALTER™ Retractor System ... fixed" retractor design available. Its wide ... surgical specialites with a versatile system ... field. Individual BOOKWALTER™ Kits are available ...
... the Alexis Wound Retractor provides circumferential ... contamination. For open surgery, the Alexis ... the incision size. For laparoscopic surgery, ... offering retraction and protection when an ...
Medicine Products: